Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of zuberitamab in primary immune thrombocytopenia
ChiCTR2100050513Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Sep 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hlx01 in immune thrombocytopenia (ITP) (4 arms), sponsored by Union Hospital. Primary endpoint: Platelet counts. Started Sep 2021; status: recruiting.
02
Drugs
hlx01
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2100050513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050513.